A Busy IPO Calendar: Forma, Repare, Progenity, Genetron

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Making a Difference for Sickle Cell Disease: Ted Love on The Long Run
Getting to Precision Medicine for I-O Combinations – It’s Even More Complicated